Focus: Abbott is a large-cap diversified healthcare company with $40.1B in FY2025 revenue, anchored in device manufacturing alongside pharmaceutical and diagnostic segments. Headquartered in Abbott Park, IL, it operates as a publicly traded entity (ABT) with global scale and multi-therapeutic presence.
Profile data last refreshed 7h ago · AI intelligence enriched 2w ago
Recent layoff filing — 53 affected
Source: state DOL filings via Big Local News
No open roles listed right now. Follow Abbott to get notified when they start hiring — the background below is worth knowing for when they do.
Abbott's cash cow, representing 70% of revenue, but facing imminent generic competition with no disclosed LOE date.
Help build intelligence for Abbott
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Abbott's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Generic antihypertensive with modest revenue; post-LOE portfolio stabilizer.
Minor product with broad but non-specific indications; approaching LOE with minimal revenue contribution.
130 discontinued, 0 duplicate formulations not shown
8-K Filing: MASIMO CORP (MASI) (CIK 0000937556) — FORM 8-K
FORM 8-K
8-K Filing: Rapport Therapeutics, Inc. (RAPP) (CIK 0002012593) — EX-99.2
EX-99.2
8-K Filing: URANIUM ENERGY CORP (UEC) (CIK 0001334933) — EXHIBIT 99.1
EXHIBIT 99.1
8-K Filing: PULSE BIOSCIENCES, INC. (PLSE) (CIK 0001625101) — PRESS RELEASE ISSUED BY PULSE BIOSCIENCES, INC. DATED APRIL 7, 2026
PRESS RELEASE ISSUED BY PULSE BIOSCIENCES, INC. DATED APRIL 7, 2026
8-K Filing: First Tracks Biotherapeutics, Inc. (TRAX) (CIK 0002091349) — EX-99.1
EX-99.1
8-K Filing: AB Private Credit Investors Corp (CIK 0001634452) — EX-10.2
EX-10.2
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Source: state DOL filings, aggregated via Big Local News
No recent compliance warnings or shortages documented, but impending DEPAKOTE ER LOE creates latent restructuring risk despite current hiring growth.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo